VTRVentas
Is the price fair?
At the top of its own P/E range. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Expensive vs its own history: P/E 154.8 vs a 38.3 median over 29 quarters (+305% vs median).
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What VTR's price assumes
Ventas trades at 155× earnings against 38.1× for the median REIT - Healthcare Facilities name, more expensive than its own group.
Trailing P/E · REIT - Healthcare Facilities median 38.1 · 4.06× the median: the market pays up for this one
- Price / sales
- 6.69
Price / sales · as of 2026-Q2
- Price / book
- 2.94
Price / book · as of 2026-Q2
- EV / sales
- 8.68
EV / sales
Details›
- Price / bookas of 2026-Q2
- 2.94
- EV / EBITas of 2026-Q2
- 266
- EV / salesas of 2026-Q2
- 8.68
- Real Estate median P/E130 names
- 25.0
- REIT - Healthcare Facilities median P/E11 names
- 38.1
- Market capitalisation
- $39.7B
| Method | Per share |
|---|---|
| What its own history would imply | not meaningful, 155× today against a 38.3× median |
| 52-week range | $65.84 – $100.56 |
| Today | $82.04 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
REIT, Healthcare Facilities
The closest names by size in the same industry